Topic Listing for TRANSITION THERAPEUTICS

Additional Information Address Principal Executive Office
Adoption New Accounting Policies Advice Beneficial Holders Securities
Aggregate Option Exercises 2008 End Values Alzheimers Disease
Amendment Stock Option Plan Amortization
Appointment Proxy Holders Appointment Remuneration Auditors
Appointment Training Monitoring Senior Management Assessment Directors Board Committees
Audit Committee Responsibilities Activities Authorized
Board Mandate Business Meeting
Capital Management Cash Equivalents Held-to-maturity Investments
Caution Regarding Forward-looking Statements Cerebrospinal Fluid
Certification Interim Filings Changes Accounting Policies
Chief Executive Officers Compensation Cica 1582 Business Combinations
Cica 1601 Consolidated Financial Statements 1602 Non-controlling Interests Cica 3064 Goodwill Intangible Assets
College Street Suite 220 Toronto Ontario Canada M5g Commitments
Comparative Consolidated Financial Statements Compensation Directors
Compensation Discussion Analysis Composition Board
Composition Compensation Committee Composition Operation
Comprehensive Loss Consolidated Financial Statements Auditors Report
Consolidated Statements Cash Flows Consolidated Statements Loss Comprehensive
Continuation Stock Option Plan Unallocated Options Contractual Obligations
Corporate Developments Corporate Performance Objectives
Critical Accounting Estimates Description Stock Option Plan
Determination Compensation Directors Officers Directors Approval
Directors Incentive Plan Awards Value Vested Earned Discharge Duties
Disclosure Controls Procedures Internal Disease Treatment Elnd005
Drug Discovery Drug Discovery Group
Drug Discovery Initiatives Elan
Elan Pharma International Limited Election Directors
Eli Lilly Elnd-005 Azd-103 Alzheimers Disease
Elnd005 Azd-103 Elnd005 Azd-103 Alzheimers Disease
Equity Based Valuations Estimated Termination Payments
Exhibits Expenditures Elnd005 Azd-103 Program
Expenditures Tt-223 Program Facility Closure
Financial Instruments Financial Liquidity
Financial Results Financial Review
Financing Activities Full Certificate
Gastrin-based Therapies General
General Administrative General Risk Factors Biotechnology Industry
Global Collaboration Agreement Elan Pharma International Limited Guarantees
Incentive Plan Awards Value Vested Earned Indebtedness Directors Executive Officers
Independence Intangible Assets
Interest Income Net Interests Certain Persons Companies Matters Acted
Interests Informed Persons Material Transactions Internal Controls Over Financial Reporting
Issued Outstanding Juvenile Diabetes Research Foundation Jdrf
Legal Requirements Licensing Collaboration Agreement Eli Lilly
Management Information Circular Managements Discussion Analysis
Managing Risk Measures Encourage Ethical Business Conduct
Monitoring Acting Nature Operations Basis Presentation
Net Assets Transferred Contractual Arrangement Next Steps
Nomination Board Members Notes Proxy
Notice Annual Meeting Shareholders Option Grants 2008
Orientation Continuing Education Board Members Other Activities
Other Arrangements Other Matters
Outlook Over Boxes
Overview Performance Graph
Phase Study Tt-223 Type Diabetes Patients Policy Statement
Position Descriptions Presentations 2009 Alzheimers Association International Conference Disease Support
Programs Proxies Submitted Received 400 Eastern Time 2008
Proxies Submitted Received 400 Eastern Time 2009 Purchase Request Completed Optionee
Receipt Common Shares Completed Optionee Recent Achievements
Recognition Deferred Revenue Reliance Experts
Report Executive Compensation Reporting Communication
Research Development Research Development Commitments
Research Development Costs Incurred Newly Formed Subsidiary Transition Resolved
Responsibilities Results Operations
Revocability Proxy Risks Uncertainties
Safe Harbor Forward-looking Statements Securities Authorized Issuance Equity Compensation Plans
See Accompanying Notes Segment Disclosure
Selected Highlights Share Capital
Shareholders Signatures
Solicitation Proxies Standard Arrangements
Stock Options Strategy Determination
Summary Compensation Table Summary Quarterly Results
Table Contents Termination Change Control Benefits
Termination Employment Change Responsibilities Contracts Total Compensation Earned
Transition Transition Therapeutics Announces 2009 End Financial Results
Transition Therapeutics Announces Appointment Vice-president Clinical Operations Transition Therapeutics Files Shelf Registration Statement
Tt-223 Clinical Development Tt-223 Combination Egf
Tt-223 Combination Glp-1 Analogue Patients Type Diabetes Tt-223 Diabetes
Tt-301 Tt-302 Valuation Allowance Future Tax Assets
Valuation Amortization Intangible Assets Verification Completed
Voting Shares Principal Holders Thereof Voting Shares Represented Management Proxies
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki